Join Arrowhead Pharmaceuticals for a virtual key opinion leader (KOL) event featuring Carel le Roux, MBChB, MSC, FRCP, FRCPath, PhD (University College Dublin), who will join members of management to discuss interim results of the Company’s Phase 1/2a studies evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-INHBE and ARO-ALK7 in adult volunteers with obesity, with and without diabetes mellitus.

The event will provide an overview of the current obesity landscape and discuss opportunities for novel treatment options. It will also describe the Activin E – ALK7 pathway in obesity and metabolic disease, a known pathway that signals the body to store fat in adipose tissue, and provide the first clinical data for Arrowhead’s ARO-INHBE and ARO-ALK7 programs.

ARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E. ARO-ALK7 is is designed to silence adipocyte expression of the ACVR1C gene to reduce production of Activin receptor-like kinase 7 (ALK7). Arrowhead’s Phase 1/2a studies of both programs are evaluating single and multiple doses of monotherapy ARO-INHBE and ARO-ALK7 in adult participants with obesity (Part 1), and in combination with tirzepatide in adult participants with obesity with and without type 2 diabetes mellitus (Part 2).

A live question and answer session will follow the formal presentations.